NASDAQ:LNTH - Lantheus Stock Price, News, & Analysis

Lantheus trades on the NASDAQ under the ticker symbol "LNTH."

Lantheus Holdings Inc (NASDAQ:LNTH) released its quarterly earnings results on Tuesday, April, 30th. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.25 by $0.03. The medical equipment provider earned $86.51 million during the quarter, compared to analyst estimates of $86.80 million. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. View Lantheus' Earnings History.

Lantheus is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Lantheus.

Lantheus issued an update on its FY 2019 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of $1.14-1.17 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.16. The company issued revenue guidance of $357.967-363.118 million, compared to the consensus revenue estimate of $360.74 million.Lantheus also updated its Q2 2019 guidance to $0.23-0.28 EPS.

2 brokers have issued twelve-month price objectives for Lantheus' shares. Their forecasts range from $20.00 to $21.00. On average, they expect Lantheus' share price to reach $20.50 in the next twelve months. This suggests that the stock has a possible downside of 24.8%. View Analyst Price Targets for Lantheus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lantheus.

News stories about LNTH stock have trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Lantheus earned a daily sentiment score of -3.1 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Lantheus.

Lantheus saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 714,800 shares, an increase of 12.4% from the April 30th total of 635,800 shares. Based on an average daily trading volume, of 375,500 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.9% of the company's stock are sold short. View Lantheus' Current Options Chain.

Some companies that are related to Lantheus include Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Trinity Biotech (TRIB), Riot Blockchain (RIOT) and Celldex Therapeutics (CLDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include Mobileye (MBBYF), CBL & Associates Properties (CBL), Gerdau (GGB), Energy Transfer LP Unit (ET), Cypress Semiconductor (CY), Endocyte (ECYT), Ares Capital (ARCC), Anavex Life Sciences (AVXL), Exelixis (EXEL) and Amicus Therapeutics (FOLD).

(LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager.

Lantheus' stock is owned by many different of institutional and retail investors. Top institutional shareholders include LSV Asset Management (4.21%), Vaughan Nelson Investment Management L.P. (4.09%), Peregrine Capital Management LLC (1.94%), JPMorgan Chase & Co. (1.88%), Lazard Asset Management LLC (0.84%) and Connor Clark & Lunn Investment Management Ltd. (0.63%). Company insiders that own Lantheus stock include A Frederick Robertson, Avista Capital Partners Gp, Ll, Brian A Markison, Cesare Orlandi, David F Burgstahler, Derace L Schaffer, John W Crowley, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Sam R Leno and Timothy G Healey. View Institutional Ownership Trends for Lantheus.

LNTH stock was sold by a variety of institutional investors in the last quarter, including AlphaOne Investment Services LLC, Gabelli Funds LLC, Royce & Associates LP, Peregrine Capital Management LLC, IndexIQ Advisors LLC, Cadence Capital Management LLC, Gamco Investors INC. ET AL and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Lantheus company stock in the last year include A Frederick Robertson, Brian A Markison, Cesare Orlandi, Derace L Schaffer, Julie Mchugh, Mary Anne Heino, Michael P Duffy and Sam R Leno. View Insider Buying and Selling for Lantheus.

LNTH stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, JPMorgan Chase & Co., CIBC World Markets Inc., Vaughan Nelson Investment Management L.P., EAM Global Investors LLC, Assenagon Asset Management S.A., Cambridge Investment Research Advisors Inc. and Spark Investment Management LLC. View Insider Buying and Selling for Lantheus.

Shares of LNTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LNTH stock can currently be purchased for approximately $27.26.

Lantheus has a market capitalization of $1.06 billion and generates $343.37 million in revenue each year. The medical equipment provider earns $40.51 million in net income (profit) each year or $0.94 on an earnings per share basis. Lantheus employs 488 workers across the globe.View Additional Information About Lantheus.

The official website for Lantheus is http://www.lantheus.com/.

Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The medical equipment provider can be reached via phone at 978-671-8001 or via email at [email protected]